13 completed, 4 terminated, 3 withdrawn, 1 enrolling by invitation. 8 Phase 2, 6 Phase 3, 3 Not applicable, 2 Phase 1, 2 Phase 4.
Follow Cerus Corporation: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCs 30-40 mL of INTERCEPT RBCs, ~30 mL of INTERCEPT RBCs plus plus 10 mL biotinylated INTERCEPT RBCs - Transfusion Reaction, Hemolytic | Phase 2 | Not yet recruiting | Cerus Corporation | 25 | 2026-10-10 | 2026-10-14 |
| Cryo-FIRST: Effectiveness of INTERCEPT Fibrinogen Complex (IFC) for Trauma-Associated Hemorrhage Pathogen Reduced Cryoprecipitated Fibrinogen Complex - Hypofibrinogenemia, Hemorrhage | Enrolling by invitation | Cerus Corporation | 320 | 2026-09-15 | 2026-10-14 | |
| Biotin-Acridine Red Cell Exchange Kinetics Pathogen reduced red blood cells - Sickle Cell Disease | Phase 2 | Withdrawn | Cerus Corporation | 2025-10-15 | 2026-09-22 | |
| A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1 INTERCEPT Blood System for RBCs, Infusion of autologous radiolabeled RBCs - Healthy Subjects | Phase 2 | Recruiting | Cerus Corporation | 120 | 2025-09-19 | 2026-09-21 |
| A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated With the INTERCEPT Blood System for Platelets With LED Illuminator. INTERCEPT Blood System for Platelets with LED Illuminator - Healthy Subjects | Phase 2 | Completed | Cerus Corporation | 40 | 2025-01-23 | 2026-08-04 |
| INTERCEPT Safety Evaluation on Whole Blood Amustaline/GSH pathogen reduction technology, Standard of Care - Safety Issues | Not applicable | Withdrawn | Swiss Transfusion SRC | 2024-01-01 | 2024-03-15 | |
| Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding Traditional Cryoprecipitate, Pathogen-Reduced Cryoprecipitate - Hypofibrinogenemia, Bleeding | Phase 4 | Completed | Weill Medical College of Cornell University | 208 | 2023-04-01 | 2025-11-21 |
| Plasma Resuscitation Without Lung Injury Pathogen-Reduced Plasma, Crystalloid Solutions - Burns | Phase 4 | Terminated | Coalition for National Trauma Research | 13 | 2022-08-17 | 2025-01-29 |
| Biotin-RBC Transfusion in SCD Biotin Labeled Red Blood Cells, Pathogen-reduced Biotin Labeled Red Blood Cells - Sickle Cell Disease | Phase 1 | Completed | Marianne Yee | 22 | 2021-10-29 | 2026-05-22 |
| In Vivo Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Apheresis Platelet Components Suspended in 100% Plasma Stored for up to 7 Days INTERCEPT Treated Platelets - Healthy | Phase 2 | Completed | Cerus Corporation | 37 | 2019-11-05 | 2022-10-27 |
| INTERCEPT Safety Evaluation in Anemic Patients INTERCEPT, Standard of Care - Anemia | Not applicable | Withdrawn | Swiss Transfusion SRC | 2019-06-01 | 2019-12-13 | |
| Recovery and Lifespan of Red Blood Cells From Pathogen-reduced, Stored Blood Units Red cell survival in INTERCEPT treated red cells - Red Cell Survival in Healthy Volunteers | Not applicable | Unknown | University of Cincinnati | 12 | 2019-01-01 | 2019-01-09 |
| Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients INTERCEPT, Control - Anemia | Phase 3 | Completed | Cerus Corporation | 581 | 2018-12-05 | 2026-09-22 |
| INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections INTERCEPT Blood System for Red Blood Cells, Conventional (Control) - Anemia | Phase 3 | Completed | Cerus Corporation | 692 | 2017-05-10 | 2026-10-06 |
| A Randomized, Multi-center, Open-label, Paired Controlled, Crossover In Vivo Study Autologous apheresis Platelet Components, prepared with the INTERCEPT Blood System for Platelets., Autologous apheresis Conventional untreated Platelet Components - Healthy | Phase 2 | Terminated | Cerus Corporation | 14 | 2015-12-01 | 2018-01-26 |
| A Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components Standard of Care - Transfusion Related Acute Lung Injury | Completed | Cerus Corporation | 2291 | 2015-12-01 | 2022-02-18 | |
| A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components INTERCEPT Platelets - Chikungunya Virus, Dengue Virus | Completed | Cerus Corporation | 90 | 2015-03-01 | 2018-10-30 | |
| A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease INTERCEPT Plasma - Acute Ebola Virus Disease | Phase 1 | Terminated | Cerus Corporation | 6 | 2014-12-01 | 2021-03-29 |
| A Controlled, In Vivo, Pilot Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Treated 7-Day Stored Apheresis Platelet Components in 35% Plasma and 65% InterSol and 7-Day Stored Apheresis Platelet Components in 100% Plasma INTERCEPT treated platelets - Healthy | Phase 2 | Completed | Cerus Corporation | 14 | 2014-12-01 | 2017-11-08 |
| Study to Assess S303 RBCs and Evaluate Safety and Efficacy in Patients Requiring Transfusion Support of Acute Anemia S-303 Red Blood Cells (RBCs) - Test, Conventional, untreated red blood cells (RBCs) - Control - Focus:Use of S303 RBCs in Patients With Acute Anemia | Phase 3 | Completed | Cerus Corporation | 81 | 2013-04-01 | 2015-08-26 |
Showing 20 of 24. Sign in to see all of them.
Anemia (4) · Transfusion Reaction (3) · Afibrinogenemia (2) · Anemia, Sickle Cell (2) · Hemorrhage (2) · Burns (1) · Hemorrhagic Fever, Ebola (1) · Leukemia (1) · Lymphoma (1) · Neoplasms (1) · Shock, Hemorrhagic (1) · Thrombocytopenia (1) · Transfusion-Related Acute Lung Injury (1) · Wounds and Injuries (1) · Zika Virus Infection (1)
Congresses as Topic (3) · Erythrocyte Count (3) · Platelet Count (2) · Crystalloid Solutions (1) · Platelet Transfusion (1) · Standard of Care (1)
United States (15) · Italy (2) · Puerto Rico (2) · Turkey (Türkiye) (2) · Germany (1) · United Kingdom (1)
Antonio Piga, MD (1) · Arndt H Kiessling, MD (1) · Edward L Snyder, MD (1) · Jerome L Gottschall, MD (1) · Jose A Cancelas-Perez, MD, PhD (1) · Katharina Madlener, Dr (1) · Larry Corash, M.D. (1) · Laura Angelici, MD (1) · Leopoldo Cancio, MD (1) · Marianne Yee, MD (1) · Melissa Cushing (1) · Paolo Rebulla, MD (1) · Raffaella Origa, MD (1) · Richard J Benjamin, MD (1) · Soraya Amar, Dr (1)
PMID 29498049, PMID 32129478, PMID 34989701, PMID 38447116, PMID 39334317, PMID 39719927, PMID 41085306, PMID 42018645, PMID 42186075
K23HL146904 (1)